The Microbiome Business & Science Briefing
MicrobimeTimes
Reporting on The Latest Microbiome Business & Scientific Developments
TRENDING
Prokarium: Leading the Evolution of Bacterial Immunotherapy, the Next Frontier in Cancer Treatment• Claude Discovers Novel Enzyme System with CRISPR-like Repeats• New Clinical Study Aims to Find Out if FMT capsules could help better manage anorexia• MaaT Pharma Provides Update on MaaT013 (Xervyteg®) Potential Development Plan Following CHMP Negative Opinion After Re-examination• Evvy Raises $40M Series B to Scale AI-Powered Precision Diagnostics & Care Platform for Women’s Health• Armata Pharmaceuticals Receives U.S. FDA Breakthrough Therapy Designation for AP-SA02•

Category: Editor’s Choice

The Human Microbiome: A Diversity of Players Ranging from Academics to Dedicated Platforms
Clinical & Manufacturing

The Human Microbiome: A Diversity of Players Ranging from Academics to Dedicated Platforms

APR 3, 2019
5-Minute Microbiome Science Roundup: March 2019
Editor's Choice

5-Minute Microbiome Science Roundup: March 2019

APR 1, 2019
Intellectual Property Considerations for the Microbiome: Personalized Strategies for a Diverse Space
Editor's Choice

Intellectual Property Considerations for the Microbiome: Personalized Strategies for a Diverse Space

MAR 25, 2019
Health for Life Capital II™, World Leading Microbiome-focused Fund Announces its First Close
Editor's Choice

Health for Life Capital II™, World Leading Microbiome-focused Fund Announces its First Close

MAR 5, 2019
Here’s What Happened at Probiota, 13-15 February in Copenhagen
Editor's Choice

Here’s What Happened at Probiota, 13-15 February in Copenhagen

MAR 1, 2019
Jeffrey Gordon wins the Frontiers of Knowledge Award for pioneering microbiome research
Editor's Choice

Jeffrey Gordon wins the Frontiers of Knowledge Award for pioneering microbiome research

FEB 14, 2019
More than 100 new gut bacteria discovered in human microbiome
Editor's Choice

More than 100 new gut bacteria discovered in human microbiome

FEB 8, 2019
Modelling Holobiont Evolution for a Better Understanding of Symbiosis, Dysbiosis, and Human Health
Editor's Choice

Modelling Holobiont Evolution for a Better Understanding of Symbiosis, Dysbiosis, and Human Health

FEB 3, 2019
Biotech Focus: An Interview with Ken Blount, CSO, Rebiotix
Editor's Choice

Biotech Focus: An Interview with Ken Blount, CSO, Rebiotix

JAN 7, 2019
EMA Rules On Omega-3 Medicinal Products – Useful Parallels for the Pharmabiotics Industry
Editor's Choice

EMA Rules On Omega-3 Medicinal Products – Useful Parallels for the Pharmabiotics Industry

DEC 21, 2018
Pharmabiotics Young Investigator Awards: Supporting Tomorrow’s Microbiome Opinion Leaders
Editor's Choice

Pharmabiotics Young Investigator Awards: Supporting Tomorrow’s Microbiome Opinion Leaders

NOV 22, 2018